Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Clinical trial NCT03969901 · COMPLETED
Trial details
- NCT number
- NCT03969901
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-08
- Primary completion
- 2024-05-07
- Enrollment
- 115
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.